• Search By Keyword

  • Document Type:

  • Organization Type:

  • Exercises:

  • Exercise Type:

 Changes to Monoclonal Antibody Ordering Process 

Situation Update: 

The increased incidence of the Delta variant of SARS-CoV-2 caused a substantial surge in the utilization of monoclonal antibody (mAb) drugs, particularly in areas of the country with low vaccination rates. As a result, the U. S. Department of Health and Human Services (HHS) changed the process to order mAb therapeutics, for either bamlanivimab and etesevimab (BAM/ETE) or casirivimab and imdevimab (REGEN-COV) on September 13. 

Edit

How Can We help?